David J Benjamin

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 33

Top Topics

Epidermal Growth Factor Receptor

Drug Administration

Small Cell Lung Cancer

Renal Cell Carcinoma

Top Venues

Nature reviews. Urology

BJU international

Future oncology (London, England)

JCO oncology practice

This page only lists publications with an associated author ORCID identifier.

Publications

David J Benjamin, Omid Yazdanpanah, Arash Rezazadeh Kalebasty
Overcoming barriers in cancer care for gender minorities. Nature reviews. Urology (2024)
David J Benjamin, Mark P Lythgoe, Arash Rezazadeh Kalebasty
Hollywood's Take on Oncology: Portrayal of Cancer in Movies, 2010-2020. JCO oncology practice (2024)
David J Benjamin, Arash Rezazadeh Kalebasty
Characterization and Survival Benefit of Drug Approvals for Metastatic Prostate Cancer, 2004 to 2022. Clinical Medicine Insights. Oncology 18 (2024)
David J Benjamin, Mark P Lythgoe, Arash Rezazadeh Kalebasty
Hollywood's Take on Oncology: Portrayal of Cancer in Movies, 2010-2020. JCO oncology practice 20 (4) (2024)
David J Benjamin, Zhaohui Arter, Nataliya Mar, Arash Rezazadeh Kalebasty
Diversifying editorial boards to mitigate the global burden of genitourinary cancers. Nature reviews. Urology 21 (7) (2024)
Robert C Hsu, Zhaohui Liao Arter, Darin Poei, David J Benjamin
A narrative review on perioperative systemic therapy in non-small cell lung cancer. Exploration of targeted anti-tumor therapy 5 (4) (2024)
David J Benjamin, Omid Yazdanpanah, Arash Rezazadeh Kalebasty
A review of vitamin use for the prevention or treatment of prostate cancer. BJU international (2024)
David J Benjamin, Omid Yazdanpanah, Arash Rezazadeh Kalebasty
Overcoming barriers in cancer care for gender minorities. Nature reviews. Urology 21 (6) (2024)
David J Benjamin, Omid Yazdanpanah, Arash Rezazadeh Kalebasty
A review of vitamin use for the prevention or treatment of prostate cancer. BJU international 134 (3) (2024)
David J Benjamin, Alyson Haslam, Vinay Prasad
Cardiovascular/anti-inflammatory drugs repurposed for treating or preventing cancer: A systematic review and meta-analysis of randomized trials. Cancer medicine 13 (5) (2024)
David J Benjamin, Zhaohui Arter, Nataliya Mar, Arash Rezazadeh Kalebasty
Diversifying editorial boards to mitigate the global burden of genitourinary cancers. Nature reviews. Urology (2024)
David J Benjamin, Mark P Lythgoe, Arash Rezazadeh Kalebasty
Hollywood's Take on Oncology: Portrayal of Cancer in Movies, 2010-2020. JCO oncology practice 20 (4) (2024)
David J Benjamin, Omid Yazdanpanah, Arash Rezazadeh Kalebasty
Overcoming barriers in cancer care for gender minorities. Nature reviews. Urology 21 (6) (2024)
David J Benjamin, Arash Rezazadeh Kalebasty
Characterization and Survival Benefit of Drug Approvals for Metastatic Prostate Cancer, 2004 to 2022. Clinical Medicine Insights. Oncology 18 (2024)
David J Benjamin, Alyson Haslam, Vinay Prasad
Cardiovascular/anti-inflammatory drugs repurposed for treating or preventing cancer: A systematic review and meta-analysis of randomized trials. Cancer medicine 13 (5) (2024)
David J Benjamin, Kyle Nolla, David Cella
Nivolumab plus cabozantinib for advanced renal cell carcinoma. Future oncology (London, England) (2023)
David J Benjamin, Anshu Shrestha, Dimitra Fellman, Rosemary D Cress, Mark P Lythgoe, Arash Rezazadeh Kalebasty
Correction: Hormonal treatment for newly diagnosed metastatic prostate cancer: a population-based study from the California cancer registry. Prostate cancer and prostatic diseases (2023)
David J Benjamin, Arash Rezazadeh Kalebasty
Treatment approaches for urachal cancer: Use of immunotherapy and targeted therapies. Rare tumors 15 (2023)
David J Benjamin, Kyle Nolla, David Cella
Nivolumab plus cabozantinib for advanced renal cell carcinoma. Future oncology (London, England) 18 (39) (2023)
David J Benjamin, Vinay Prasad
Reevaluating Adjuvant Capecitabine for Resected Biliary Tract Cancer. The oncologist (2023)
David J Benjamin, Kyle Nolla, David Cella
Nivolumab plus cabozantinib for advanced renal cell carcinoma. Future oncology (London, England) 18 (39) (2023)
David J Benjamin, Kyle Nolla, David Cella
Nivolumab plus cabozantinib for advanced renal cell carcinoma. Future oncology (London, England) 18 (39) (2023)
David J Benjamin, Mark P Lythgoe, Arash Rezazadeh
Financial toxicity from newly approved second-/third-line agents in metastatic urothelial carcinoma. BJU international (2023)
David J Benjamin, Anshu Shrestha, Dimitra Fellman, Rosemary D Cress, Mark P Lythgoe, Arash Rezazadeh Kalebasty
Hormonal treatment for newly diagnosed metastatic prostate cancer: a population-based study from the California cancer registry. Prostate cancer and prostatic diseases (2023)
David J Benjamin, Mark P Lythgoe, Arash Rezazadeh
Financial Toxicity from Newly Approved Second-/Third-Line Agents in Metastatic Urothelial Carcinoma. BJU international (2023)
Robert C Hsu, David J Benjamin, Misako Nagasaka
The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer-A Narrative Review. Cancers 15 (14) (2023)
David J Benjamin, Arash Rezazadeh Kalebasty
Patient preferences in the treatment of genitourinary cancers. Nature reviews. Urology (2023)
David J Benjamin, Mark P Lythgoe
The FDA's latest draft guidance on accelerated approvals - one step forward, two steps back? Nature reviews. Clinical oncology (2023)
David J Benjamin, Misako Nagasaka
Freeing the Competition: Will Aumolertinib (AENEAS) Have a Fighting Chance Against Osimertinib (FLAURA)? Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
David J Benjamin, Nataliya Mar, Arash Rezazadeh Kalebasty
Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma. Clinical Medicine Insights. Oncology 16 (2022)
David J Benjamin, Arash Rezazadeh
Quality of life in sexual minorities following prostate cancer treatment. Nature reviews. Urology 19 (6) (2022)
David J Benjamin, Alyson Haslam, Jenny Gill, Vinay Prasad
Targeted therapy in lung cancer: Are we closing the gap in years of life lost? Cancer medicine 11 (18) (2022)
David J Benjamin, Yung Lyou
Advances in Immunotherapy and the TGF-β Resistance Pathway in Metastatic Bladder Cancer. Cancers 13 (22) (2021)